Peer-influenced content. Sources you trust. No registration required. This is HCN.
MDLinx
“It’s a hypothesis grounded in measurable physiology that brings together many pieces of existing evidence.” — Jose-Manuel Alonso, Visual Neuroscientist, SUNY College of Optometry
Optometry March 9th 2026
Vision Monday
“When screen time reaches this level, regular eyecare becomes essential, not optional.” — Valerie Sheety-Pilon, OD, VSP Vision Care SVP of Clinical and Medical Affairs
Review of Optometry
“Recurrent or non-resolving ‘chalazia’ are among the most common masquerades of sebaceous carcinoma, highlighting the need for histopathological evaluation.” — Bhawan Minhas, OD
Ophthalmology March 9th 2026
Ophthalmology Advisor
The combined action of the drugs results in pupil constriction, resulting in a pinhole effect that improves near visual acuity and depth of focus in patients with presbyopia.
Eyewire+
“When patients truly understand their procedure, clinics run more smoothly and outcomes improve.” — Dr. Stanley Windsor, Head of Digital Health, Rayner
Retinal Physician
“Axpaxli is the first and only investigational product in wet AMD with a novel mechanism of action to successfully demonstrate superiority to an approved anti-VEGF agent since their initial approval more than 20 years ago.” — Pravin U. Dugel, MD, Ocular Therapeutix